373 related articles for article (PubMed ID: 35762406)
21. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease.
Ding K; Li Z; Lu Y; Sun L
Eur J Intern Med; 2023 Sep; 115():114-127. PubMed ID: 37328398
[TBL] [Abstract][Full Text] [Related]
23. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
[TBL] [Abstract][Full Text] [Related]
24. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
Raj R
Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
[TBL] [Abstract][Full Text] [Related]
25. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Goulooze SC; Snelder N; Seelmann A; Horvat-Broecker A; Brinker M; Joseph A; Garmann D; Lippert J; Eissing T
Clin Pharmacokinet; 2022 Mar; 61(3):451-462. PubMed ID: 34786651
[TBL] [Abstract][Full Text] [Related]
26. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
[TBL] [Abstract][Full Text] [Related]
27. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Filippatos G; Pitt B; Agarwal R; Farmakis D; Ruilope LM; Rossing P; Bauersachs J; Mentz RJ; Kolkhof P; Scott C; Joseph A; Bakris GL; Anker SD;
Eur J Heart Fail; 2022 Jun; 24(6):996-1005. PubMed ID: 35239204
[TBL] [Abstract][Full Text] [Related]
28. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Filippatos G; Anker SD; Agarwal R; Ruilope LM; Rossing P; Bakris GL; Tasto C; Joseph A; Kolkhof P; Lage A; Pitt B;
Circulation; 2022 Feb; 145(6):437-447. PubMed ID: 34775784
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B; Filippatos G; Agarwal R; Anker SD; Bakris GL; Rossing P; Joseph A; Kolkhof P; Nowack C; Schloemer P; Ruilope LM;
N Engl J Med; 2021 Dec; 385(24):2252-2263. PubMed ID: 34449181
[TBL] [Abstract][Full Text] [Related]
30. [Finerenone (Kerendia®), a new weapon against the chronic kidney disease of a patient with type 2 diabetes].
Scheen A; Delanaye P
Rev Med Liege; 2023 Dec; 78(12):725-732. PubMed ID: 38095038
[TBL] [Abstract][Full Text] [Related]
31. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.
Chen X; Li X; Zhang K; Lian K; Zhang W; Song Y; Kan C; Zhang J; Han F; Sun X; Guo Z
Clin Exp Nephrol; 2024 Feb; 28(2):125-135. PubMed ID: 37847437
[TBL] [Abstract][Full Text] [Related]
32. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
[TBL] [Abstract][Full Text] [Related]
33. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
Doggrell SA
Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
[No Abstract] [Full Text] [Related]
34. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
Agarwal R; Filippatos G; Pitt B; Anker SD; Rossing P; Joseph A; Kolkhof P; Nowack C; Gebel M; Ruilope LM; Bakris GL;
Eur Heart J; 2022 Feb; 43(6):474-484. PubMed ID: 35023547
[TBL] [Abstract][Full Text] [Related]
35. Effects of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, on Cardiovascular Disease, Chronic Kidney Disease, and Blood Pressure.
Ravid JD; Laffin LJ
Curr Cardiol Rep; 2022 Oct; 24(10):1251-1259. PubMed ID: 35925515
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic perspective: evolving evidence of nonsteroidal mineralocorticoid receptor antagonists in diabetic kidney disease.
Yao L; Liang X; Wang P
Am J Physiol Endocrinol Metab; 2023 Jun; 324(6):E531-E541. PubMed ID: 37166263
[TBL] [Abstract][Full Text] [Related]
38. When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases.
Kobayashi M; Girerd N; Zannad F
Nephrol Dial Transplant; 2024 Jun; 39(7):1063-1072. PubMed ID: 38192033
[TBL] [Abstract][Full Text] [Related]
39. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Filippatos G; Anker SD; August P; Coats AJS; Januzzi JL; Mankovsky B; Rossing P; Ruilope LM; Pitt B; Sarafidis P; Teerlink JR; Kapelios CJ; Gebel M; Brinker M; Joseph A; Lage A; Bakris G; Agarwal R
Eur Heart J Cardiovasc Pharmacother; 2023 Feb; 9(2):183-191. PubMed ID: 36639130
[TBL] [Abstract][Full Text] [Related]
40. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Filippatos G; Bakris GL; Pitt B; Agarwal R; Rossing P; Ruilope LM; Butler J; Lam CSP; Kolkhof P; Roberts L; Tasto C; Joseph A; Anker SD;
J Am Coll Cardiol; 2021 Jul; 78(2):142-152. PubMed ID: 34015478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
